REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 4.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 214,353 shares of the biotechnology company’s stock after selling 11,064 shares during the quarter. Principal Financial Group Inc.’s holdings in REGENXBIO were worth $2,249,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of RGNX. Barclays PLC raised its holdings in REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock worth $1,217,000 after purchasing an additional 67,948 shares in the last quarter. Integral Health Asset Management LLC lifted its stake in shares of REGENXBIO by 25.0% in the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after buying an additional 190,000 shares during the last quarter. Quest Partners LLC lifted its position in shares of REGENXBIO by 11,731.0% during the 2nd quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock worth $491,000 after purchasing an additional 41,645 shares during the last quarter. BNP Paribas Financial Markets increased its position in REGENXBIO by 602.9% during the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 17,533 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in REGENXBIO by 630.9% in the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock valued at $1,711,000 after acquiring an additional 126,249 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Performance

RGNX stock opened at $7.77 on Friday. The company’s 50-day simple moving average is $9.07 and its 200 day simple moving average is $10.79. REGENXBIO Inc. has a 52 week low of $7.14 and a 52 week high of $28.80. The company has a market capitalization of $384.96 million, a PE ratio of -1.54 and a beta of 1.24.

Analyst Upgrades and Downgrades

RGNX has been the topic of several analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price objective on shares of REGENXBIO in a research note on Wednesday, December 11th. Raymond James reiterated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. Morgan Stanley restated an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, HC Wainwright reduced their target price on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.